Company intelligence / Profile preview

Agnos Therapeutics

Baltimore, Maryland, United States

Ownership: Private
Development stage: Other

Overview

Mission is to dramatically improve the standard of care for millions suffering from inherited blindness by developing a novel, likely-gene-therapy-based therapeutic platform. No clinical results publicly available as of 2025; appears to be preclinical/early-stage startup

Therapeutic areas: Ophthalmology
Modalities: Gene therapy
Industry: Biotech

Drug pipeline

1 asset

AGN-001

Preclinical

Beyond the preview

Go deeper on Agnos Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Agnos Therapeutics.

Explore the full profile